Cargando…

Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial

BACKGROUND: AmBisome(® )is an efficacious, safe anti-leishmanial treatment. There is growing interest in its use, either as a single dose or in combination treatments. In East Africa, the minimum optimal single-dosage has not been identified. METHODS/DESIGN: An open-label, 2-arm, non-inferiority, mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edwards, Tansy, Omollo, Raymond, Khalil, Eltahir AG, Yifru, Sisay, Musa, Brima, Musa, Ahmed, Wasunna , Monique, Smith, Peter G, Royce, Catherine, Ellis, Sally, Balasegaram, Manica, Hailu, Asrat
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061925/ https://www.ncbi.nlm.nih.gov/pubmed/21375777 http://dx.doi.org/10.1186/1745-6215-12-66

Ejemplares similares

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
por: Khalil, Eltahir A. G., et al.
Publicado: (2014)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion
por: Nath, Proggananda, et al.
Publicado: (2014)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome(®) and AmBisome(®) in murine cutaneous leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
por: Musa, Ahmed M., et al.
Publicado: (2010)

Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh
por: Lucero, Emiliano, et al.
Publicado: (2015)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
por: Rahman, Ridwanur, et al.
Publicado: (2017)

Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome)
por: Burza, Sakib, et al.
Publicado: (2014)

Cytotoxicity of Amphotericin B and AmBisome: In Silico and In Vivo Evaluation Employing the Chick Embryo Model
por: Khosravi, Ahmad, et al.
Publicado: (2022)

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Omollo, Raymond, et al.
Publicado: (2011)

Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

A Comparison of AmBisome(®) to Amphotericin B for Treatment of Systemic Candidiasis in Very Low Birth Weight Infants
por: Jeon, Ga Won, et al.
Publicado: (2007)

AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial( )
por: Burza, Sakib, et al.
Publicado: (2022)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study
por: Abongomera, Charles, et al.
Publicado: (2018)

Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis
por: Forrester, Sarah, et al.
Publicado: (2019)

Parasitic Loads in Tissues of Mice Infected with Trypanosoma cruzi and Treated with AmBisome
por: Cencig, Sabrina, et al.
Publicado: (2011)

The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles
por: Walker, Louise, et al.
Publicado: (2018)

The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
por: Wasunna, Monique, et al.
Publicado: (2016)

Visceral Leishmaniasis: New Health Tools Are Needed
por: Hailu, Asrat, et al.
Publicado: (2005)

Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
por: Tamiru, Aschalew, et al.
Publicado: (2016)

Hypokalaemia-Induced Rhabdomyolysis after Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL) with High-Dose AmBisome in Bangladesh—A Case Report
por: Marking, Ulrika, et al.
Publicado: (2014)

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
por: Musa, Ahmed, et al.
Publicado: (2012)

AmBisome Induced Avascular Necrosis of the Alae of the Nose of a very young girl suffering from Kala‐azar – a Case Report
por: Maruf, Shomik, et al.
Publicado: (2016)

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
por: Kimutai, Robert, et al.
Publicado: (2017)

Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial
por: Hailu, Asrat, et al.
Publicado: (2010)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

The Economic Burden of Visceral Leishmaniasis in Sudan: An Assessment of Provider and Household Costs
por: Meheus, Filip, et al.
Publicado: (2013)

Liposomal amphotericin B as a treatment for human leishmaniasis
por: Balasegaram, Manica, et al.
Publicado: (2012)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
por: Lawrence, David S., et al.
Publicado: (2018)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study
por: Ponatshego, Ponego Lloyd, et al.
Publicado: (2019)

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
por: Lawrence, David S., et al.
Publicado: (2019)

Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
Publicado: (2014)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
Publicado: (2014)

AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial
por: Molefi, Mooketsi, et al.
Publicado: (2015)

Validation of Two Rapid Diagnostic Tests for Visceral Leishmaniasis in Kenya
por: Mbui, Jane, et al.
Publicado: (2013)

Peroral Amphotericin B Polymer Nanoparticles Lead to Comparable or Superior In Vivo Antifungal Activity to That of Intravenous Ambisome(®) or Fungizone™
por: Italia, Jagdishbhai L., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_v4g4rcdqt2hailr7vlvperho82